Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.74 |
| ▸ | MBOAT4 | Q96T53 | 4/20 | 0.74 |
| ▸ | USP7 | Q93009 | 2/20 | 0.74 |
| ▸ | STAT3 | P40763 | 2/20 | 0.74 |
| ▸ | USP2 | O75604 | 1/20 | 0.74 |
| ▸ | RORC | P51449 | 1/20 | 0.66 |
| ▸ | NOS2 | P35228 | 7/20 | 0.60 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | CCR6 | P51684 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84163 | 1.00 | NFE2L2 (0.74) | NFE2L2MBOAT4USP7STAT3USP2 | |
| SCHEMBL12125024 | 0.92 | NFE2L2 (0.63) | NFE2L2MBOAT4USP7STAT3USP2 | |
| SCHEMBL83735 | 0.92 | NFE2L2 (0.63) | NFE2L2MBOAT4USP7STAT3USP2 | |
| SCHEMBL15382999 | 0.92 | NFE2L2 (0.74) | NFE2L2MBOAT4USP7STAT3USP2 | |
| SCHEMBL15382991 | 0.92 | NFE2L2 (0.74) | NFE2L2MBOAT4USP7STAT3USP2 | |
| SCHEMBL12447444 | 0.91 | NFE2L2 (0.62) | NFE2L2MBOAT4USP7STAT3USP2 | |
| SCHEMBL82945 | 0.91 | NOS2 (0.73) | NFE2L2MBOAT4USP7STAT3USP2 | |
| SCHEMBL82937 | 0.91 | CYP3A4 (0.73) | NFE2L2MBOAT4USP7STAT3USP2 | |
| SCHEMBL12447479 | 0.91 | CYP3A4 (0.73) | NFE2L2MBOAT4USP7STAT3USP2 | |
| SCHEMBL13393866 | 0.91 | CYP3A4 (0.73) | NFE2L2MBOAT4USP7STAT3USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290455-B2 | CDDO-Me amino acid conjugates and methods of use | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2016-03-22 | — | — | US | disclosed |
| US-9205113-B2 | Synthetic triterpenoids and methods for modulating stem/progenitor cell gene expression | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150225352-A1 | CDDO-ME AMINO ACID CONJUGATES AND METHODS OF USE | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2015-08-13 | — | — | US | disclosed |
| US-20150104429-A1 | SYNTHETIC TRITERPENOIDS AND METHODS FOR MODULATING STEM/PROGENITOR CELL GENE EXPRESSION | TRUSTEES OF DARTMOUTH COLLEGE | 2015-04-16 | — | — | US | disclosed |
| US-20140377235-A1 | METHODS FOR USING SYNTHETIC TRITERPENOIDS IN THE TREATMENT OF BONE OR CARTILAGE DISEASES OR CONDITIONS | TRUSTEES OF DARTMOUTH COLLEGE | 2014-12-25 | — | — | US | disclosed |
| US-20130122053-A1 | SYNTHETIC TRITERPENOIDS AND TRICYCLIC-BIS-ENONES FOR USE IN STIMULATING BONE AND CARTILAGE GROWTH | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2013-05-16 | — | — | US | disclosed |
| US-8440820-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring | REATA PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20120283450-A1 | COMPOUNDS INCLUDING AN ANTI-INFLAMMATORY PHARMACORE AND METHODS OF USE | REATA PHARMACEUTICALS, INC. | 2012-11-08 | — | — | US | disclosed |
| US-8299046-B2 | Increasing the expression of TGF- beta -dependent genes; inducing new bone formation | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120245374-A1 | Antioxidant Inflammation Modulators: Oleanolic Acid Derivatives with Saturation in the C-Ring | REATA PHARMACEUTICALS, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-8034955-B2 | triterpenoids such as 2-cyano-3,12-dioxoolean-1,9-dien-28oic acid, used for inhibiting gamma -inteferon-induced nitric oxide production in macrophages; preventing cancer, Alzheimer's disease, Parkinson's disease, inflammatory bowel diseases, and multiple sclerosis | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2011-10-11 | — | — | US | disclosed |
| US-7863327-B2 | Therapeutic compounds and methods of use | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2011-01-04 | — | — | US | disclosed |
| US-20090048205-A1 | COMBINATION THERAPY WITH SYNTHETIC TRITERPENOIDS AND GEMCITABINE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2009-02-19 | — | — | US | disclosed |
| US-20080233195-A1 | SYNTHETIC TRITERPENOIDS AND TRICYCLIC-BIS-ENONES FOR USE IN STIMULATING BONE AND CARTILAGE GROWTH | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080220057-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150104429-A1 | SYNTHETIC TRITERPENOIDS AND METHODS FOR MODULATING STEM/PROGENITOR CELL GENE EXPRESSION | BMP2, BMPR2, BMP4 | NFE2L2 1795/4885MBOAT4 4782/4885USP7 3292/4885 |
| US-20140377235-A1 | METHODS FOR USING SYNTHETIC TRITERPENOIDS IN THE TREATMENT OF BONE OR CARTILAGE DISEASES OR CONDITIONS | BMP2, BMP4, BMP1 | NFE2L2 619/4885MBOAT4 2029/4885USP7 3145/4885 |
| US-20130122053-A1 | SYNTHETIC TRITERPENOIDS AND TRICYCLIC-BIS-ENONES FOR USE IN STIMULATING BONE AND CARTILAGE GROWTH | BMP4, BMP2, BMP1 | NFE2L2 1294/4885MBOAT4 2413/4885USP7 4181/4885 |
| US-20090048205-A1 | COMBINATION THERAPY WITH SYNTHETIC TRITERPENOIDS AND GEMCITABINE | RABGGTB, BAD, PGGT1B | NFE2L2 1455/4885MBOAT4 1132/4885USP7 3609/4885 |
| US-20150225352-A1 | CDDO-ME AMINO ACID CONJUGATES AND METHODS OF USE | DAO, DDO, HAAO | NFE2L2 743/4885MBOAT4 217/4885USP7 1432/4885 |
| US-20120245374-A1 | Antioxidant Inflammation Modulators: Oleanolic Acid Derivatives with Saturation in the C-Ring | HMOX1, ALOX12, ALOX15 | NFE2L2 4/4885MBOAT4 650/4885USP7 1310/4885 |
| US-20120283450-A1 | COMPOUNDS INCLUDING AN ANTI-INFLAMMATORY PHARMACORE AND METHODS OF USE | PTGES, PTGS1, PTGES2 | NFE2L2 555/4885MBOAT4 3228/4885USP7 3375/4885 |
| US-20080233195-A1 | SYNTHETIC TRITERPENOIDS AND TRICYCLIC-BIS-ENONES FOR USE IN STIMULATING BONE AND CARTILAGE GROWTH | BMP4, BMP2, BMP1 | NFE2L2 1294/4885MBOAT4 2413/4885USP7 4181/4885 |
| US-20080220057-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | PARK7, MGMT, SNCA | NFE2L2 50/4885MBOAT4 1732/4885USP7 2731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.